Article R5121-5-2 of the French Public Health Code
Except where there is a risk to patients’ health, the proprietary medicinal products mentioned in b of 5° of Article L. 5121-1 which are presented in a modified-release oral pharmaceutical form different from that of the reference proprietary medicinal product are identified by a decision of the Director General of the Agence nationale de sécurité du médicament et des produits de santé mentioning the corresponding reference proprietary medicinal product. This…